BioSpace News Archive

Capstone Therapeutics (OTCQB: CAPS) (“the Company”) RECAPITALIZATION OF AND MERGER WITH TOTALSTONE LLC In March 2020, the Company entered into an agreement, which will be effective April 1, 2020, to obtain an interest in materials distribution company (TotalStone, LLC), which distributes masonry stone products for residential and commercial construction in the Midwest and Northeast United States under the trade names Instone and Northeast

Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes

Honduras President Juan Orlando Hernández announced the immediate roll out of an economic aid plan to fully address the main needs of the population amid the sanitary emergency caused by COVID-19 and its consequences.

Mylan N.V. (NASDAQ: MYL) and Lupin Limited (Lupin) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Nepexto®

Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced receiving CE (Conformité Européene) Mark approval for the GEN2 Pure-Vu System.

National Association for Biomedical Research President Matthew R. Bailey issued the following statement regarding the need to streamline transportation of animals used domestically in medical research, particularly during the current coronavirus pandemic..

Jumptuit Health, Inc. announced today the establishment of a Task Force to implement a National Individualized Health Alert System (NIHAS) for COVID-19 and other infectious diseases.

Rising Pharma Holdings Inc., the global pharmaceutical company operating as Rising Pharmaceuticals, today announced its collaborative agreement with the Division of Infectious Disease and International Medicine at the University of Minnesota, Department of Infectious Disease on a clinical trial exploring hydroxychloroquine as preventive treatment for coronavirus disease 2019 (COVID-19)

The U.S. Food and Drug Administration took action to help increase the supply of ventilators, ventilator tubing connectors, and ventilator accessories, as well as filtering facepiece respirators (FFRs) due to shortages during COVID-19, as part of our commitment to ease burdens on the health care system during this pandemic.

CZI Joins Bill & Melinda Gates Foundation, Wellcome, Mastercard in Standing up “COVID-19 Therapeutics Accelerator”